Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups
Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups
Guttman-Yassky E, Katoh N, Cork MJ, et al. Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups. J Drugs Dermatol. 2025;24(2):167-173. doi:10.36849/JDD.85852.
Introduction
Lichenification, characterized by thickened, leathery skin resulting from chronic scratching and inflammation, is a challenging clinical manifestation frequently observed in patients with moderate to severe atopic dermatitis (AD). This symptom significantly impairs patient quality of life and complicates disease management across all demographic groups.
The present post hoc analysis combines data from five randomized clinical trials to comprehensively evaluate dupilumab’s efficacy in reducing lichenification among patients with moderate to severe AD. Importantly, this analysis stratifies outcomes by both age and racial subgroups, addressing gaps in understanding dupilumab’s effects in diverse populations and supporting personalized therapeutic strategies.
Study Overview
This post hoc analysis pooled data from five previously completed clinical trials (NCT03054428, NCT03345914, NCT02277743, NCT02277769, and NCT02395133), including 1,997 patients aged 6 to 88 years with moderate to severe AD and diverse racial backgrounds.
Study Type: Post hoc pooled analysis of randomized controlled trials
Population: 1,997 patients with moderate to severe AD, ages 6 to 88 years
Age Subgroups:
- Children (placebo: 123, dupilumab: 244)
- Adolescents (placebo: 85, dupilumab: 166)
- Adults (placebo: 460, dupilumab: 457)
Racial Subgroups:
- Asian (placebo: 132, dupilumab: 234)
- Black/African American (placebo: 74, dupilumab: 112)
- White (placebo: 427, dupilumab: 923)
Intervention: Dupilumab versus placebo treatment
Outcome Measures: Changes in lichenification assessed by Global Individual Signs Score, SCORing Atopic Dermatitis (SCORAD), and Eczema Area and Severity Index (EASI)
The analysis focused on evaluating the onset, magnitude, and durability of lichenification improvement across demographic subgroups, employing nominal statistical significance thresholds.
Key Findings
- Dupilumab produced statistically significant (nominal) reductions in Global Individual Signs Score lichenification versus placebo across all age groups, with a rapid onset of improvement starting at week 1 for adults and adolescents, and week 2 for children.
- The improvement in lichenification was sustained through week 16, demonstrating durable clinical benefit.
- Consistent improvements were also observed across other validated scoring systems measuring atopic dermatitis severity, including SCORAD and EASI indices.
- By week 16, dupilumab showed nominally significant improvements in lichenification for all examined racial groups (Asian, Black/African American, White), supporting broad efficacy across diverse populations.
- The extent of lichenification improvement did not substantially differ between race groups, underscoring dupilumab’s applicability in a multicultural patient population.
Evidence Synthesis
The findings from this comprehensive pooled post hoc analysis align with and extend the existing evidence base supporting dupilumab’s efficacy in atopic dermatitis across age and severity spectrums.
Key Supporting Studies Include:
- Simpson EL et al., 2016: The pivotal SOLO 1 and 2 Phase 3 RCTs established dupilumab’s efficacy in adults with moderate to severe AD, demonstrating improvements in key clinical signs (PMID: 27690741).
- Paller AS et al., 2022: Demonstrated dupilumab efficacy in very young children (6 months to under 6 years) in a randomized Phase 3 trial (PMID: 36116481), underscoring its early-life therapeutic potential.
- Blauvelt A et al., 2017: The LIBERTY AD CHRONOS 52-week trial confirmed sustained dupilumab efficacy with concomitant topical corticosteroids in adults (PMID: 28478972).
- Silverberg JI et al., 2022: Post hoc analyses from SOLO trials confirmed consistent dupilumab efficacy regardless of age at disease onset, supporting broad clinical utility (PMID: 36269503).
- Paller AS et al., 2023: A post hoc assessment showed rapid, significant dupilumab benefits even in patients with erythrodermic atopic dermatitis, the most severe AD subset (PMID: 36723913).
Comparative Summary Table: Key RCT Evidence of Dupilumab Efficacy in AD
| Study | Population | Intervention | Primary Endpoint | Key Findings |
|---|---|---|---|---|
| Simpson EL et al., 2016 (SOLO 1 & 2) | Adults with moderate to severe AD | Dupilumab monotherapy | Improvement in EASI score at week 16 | Significant AD symptom and sign improvement vs placebo |
| Paller AS et al., 2022 | Children 6 mo to < 6 yrs with uncontrolled AD | Dupilumab monotherapy | Reduction in eczema severity (EASI) | Rapid improvement and good safety profile |
| Blauvelt A et al., 2017 (CHRONOS) | Adults with moderate to severe AD | Dupilumab + topical corticosteroids | Long-term disease control at 52 weeks | Sustained efficacy with combination therapy |
| Silverberg JI et al., 2022 | Adults with varying age of disease onset | Dupilumab monotherapy | Consistent efficacy across age of onset subgroups | Robust, subgroup-independent treatment responses |
| Paller AS et al., 2023 | Erythrodermic AD patients (severe disease) | Dupilumab monotherapy | Clinical symptom severity reduction | Rapid and significant improvement observed |
Evidence Gaps: Despite robust evidence, no studies have designated lichenification as a primary endpoint, and there are no direct head-to-head trials comparing dupilumab’s effect on lichenification against other systemic AD therapies.
Clinical Implications
- Dupilumab provides rapid and sustained improvement in lichenification, a key and often difficult-to-treat manifestation of atopic dermatitis, across all age groups.
- Consistent efficacy across racial subgroups supports dupilumab’s broad therapeutic applicability in diverse patient populations.
- Clinicians should consider dupilumab as an effective systemic option for moderate to severe AD patients presenting with lichenification, including children, adolescents, and adults.
Strengths & Limitations
| Strengths | Limitations |
|---|---|
| Large pooled sample (N=1,997) enabling subgroup analyses across age and race. | Post hoc nature of analysis limits causal inference relative to pre-planned endpoints. |
| Inclusion of diverse racial groups enhances generalizability. | No primary endpoint specifically targeting lichenification improvement. |
| Comprehensive assessment using multiple validated scoring systems (Global Individual Signs Score, SCORAD, EASI). | Absence of direct head-to-head comparator therapies for lichenification limits comparative effectiveness conclusions. |
| Rapid onset and sustained improvements observed enhance clinical relevance. | Nominal statistical significance reported without multiplicity correction may risk type I error. |
Future Directions
Future clinical trials should prioritize lichenification as a primary endpoint with prospective design to confirm these benefits. Direct head-to-head comparisons with alternative systemic treatments are also warranted to delineate relative efficacy and safety profiles specific to lichenification improvement.
Listen to the Podcast
A short discussion of today’s highlight.
References
- Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi:10.1056/NEJMoa1610020. PMID: 27690741.
- Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2285-2303. doi:10.1016/S0140-6736(17)31191-1. PMID: 28478972.
- Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 Sep 17;400(10356):908-919. doi:10.1016/S0140-6736(22)01539-2. PMID: 36116481.
- Silverberg JI, Boguniewicz M, Hanifin J, et al. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials. Dermatol Ther (Heidelb). 2022;12(12):2731-2746. doi:10.1007/s13555-022-00827-0. PMID: 36269503.
- Paller AS, Silverberg JI, Cork MJ, et al. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials. JAMA Dermatol. 2023;159(3):255-266. doi:10.1001/jamadermatol.2022.6312. PMID: 36723913.
